The effects of somatostatin in the polycystic ovary syndrome

Journal of Obstetrics and Gynaecology

Volumn 17, Issue 6, 1997, Pages 560-564

  Rosina, Barbara ^a,b   De Fusco, Donatella ^a   Falsetti, L ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; FOLLITROPIN; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; OCTREOTIDE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN; SRS 201 995; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL;

EID: 0031463288     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443619768614     Document Type: Article

References (50)

1. Açbay O. and Gundogdu S. (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertility and Sterility, 65, 946-949.
2. Adashi E. Y., Hsueh A. J. W. and Yen S. S. C. (1981) Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology, 108, 1441-1449.
3. Adashi E. Y., Resnick C. E., D'Ercole J. A., Svoboda J. E. and Van Wyk J. J. (1985) Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocrine Reviews, 6, 400-420.
4. Adashi E. Y., Resnick C. E., Hernandez E. R., Svoboda M. E. and Van Wyk J. J. (1988) In vivo regulation of granulosa cell somatomedin-C/insulin-like growth factor I receptors. Endocrinology. 122, 1383-1389.
5. Anttila L., Koskinen P., Jaatinen T., Erkkola R., Irjala K. and Ruutiainen K. (1993) Insulin hypersecretion together with high luteinizing hormone concentration augments androgen secretion in oral glucose tolerance test in women with polycystic ovarian disease. Human Reproduction, 8, 1179-1183.
6. Barbieri R. L. Smith S. and Ryan K. J. (1988) The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertility and Sterility, 50, 197-212.
7. Bauer W., Briner V., Doepfner W., Haller R., Huguenin R., Marbach P. and Petcher T. J. (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences, 31, 1133-1140.
8. Bloom S. R. and Polak J. M. (1987) Somatostatin. British Medical Journal, 295, 288-290.
9. Blumenfeld Z. and Lunenfeld B. (1989) The potentiating effect of growth hormone on follicle stimulation with human menopausal gonadotropin in a panhypopituitary patient. Fertility and Sterility, 52, 328-331.
10. Ciaraldi T. P., El-Roeiy A., Madar Z., Reichart D., Olefsky J. M. and Yen S. S. C. (1992) Cellular mechanism of insulin resistance in polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 75, 577-582.
11. Clausen J., Hansen T., Bjobaek C., Echwalds S., Urhammer S., Rasmussen S., Andersen C., Hansen L., Almind K., Winther K., Haraldsdottir J. and Borch-Johnsen K. (1995) Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet, 346, 397-402.
12. Conway G. S. and Jacobs H. S. (1993) Clinical implications of hyperinsulinemia in women. Clinical Endocrinology, 39, 623-632.
13. Dale P. O., Tanbo T., Vaaler S. and Abyholm T. (1992) Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertility and Sterility, 58, 487-491.
14. Doldi N., Bassan M., Bonzi V. and Ferrari A. (1996) Effects of growth hormone and growth hormone-releasing hormone on steroid synthesis in cultured human luteinizing granulosa cells. Gynecological Endocrinology, 10, 101-108.
15. Dunaif A., Mandeli J., Fluhr H. and Dobrjansky A. (1988) The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 66, 131-139.
16. Dunaif A., Segal K. R., Shelley D. R., Green G., Dobrjansky A. and Licholai T. (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes, 41, 1257-1266.
17. Dunaif A., Scott D., Finegood D., Quintana B. and Whitcomb R. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81, 3299-3305.
18. Ferriman D. and Gallway J. D. (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism, 21, 1440-1448.
19. Franks S. (1995) Polycystic ovary syndrome. New England Journal of Medicine, 333, 853-861.
20. Fulghesu A. M., Lanzone A., Andreani C. L., Pierro E., Caruso A. and Mancuso S. (1995) Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertility and Sterility, 64, 703-708.
21. Homburg R., Eshel A., Abdalla H. I. and Jacobs H. S. (1988) Growth hormone facilitates ovulation induction by gonadotropins. Clinical Endocrinology, 29, 113-117.
22. Homburg R., Pariente C., Lunenfeld B. and Jacobs H. S. (1992) The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Human Reproduction, 7, 1379-1383.
23. Hull M. G. R. (1987) Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecological Endocrinology, 1, 235-245.
24. Jahanfar S., Eden J. A., Warren P., Seppala M. and Nguyen T. V. (1995) A twin study of polycystic ovary syndrome. Fertility and Sterility, 63, 478-486.
25. Jia X. C., Kamljn J., and Hsueh A. J. W. (1986) Growth hormone enhances follicle-stimulating hormone-induced differentiation of cultured rat granulosa cells. Endocrinology, 118, 1401-1409.
26. Kutz K., Nueesch E. and Rosenthaler J. (1986) Pharmacokinetics of SMS 201-995 in healthy subjects. Scandinavian Journal of Gastroenterology, 119, supplement, 65-72.
27. Lanzone A., Fulghesu A. M., Andreani C. L., Apa R., Fortini A., Caruso A. and Mancuso S. (1990) Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by Gn-RH agonist. Human Reproduction, 5, 143-149.
28. Longnecker S. M. (1988) Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intelligence and Clinical Pharmacy, 22, 99-106.
29. Martin J. L. and Baxter R. C. (1994) Regulation and actions of the insulin-like growth factor binding proteins. Current Opinion in Endocrinology and Diabetes, 16-21.
30. Morris D. V. and Falcone T. (1996) The relationship between insulin sensitivity and insulin-like growth factor-binding protein-1. Gynecological Endocrinology, 10, 407-412.
31. Morris R. S., Carmina E., Vijod M. A., Stanczyk F. Z. and Lobo R. A. (1995) Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. Fertility and Sterility, 63, 742-746.
32. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28, 1039-1057.
33. Owen E. J., Shoham Z., Mason B. A., Ostergaard H. and Jacobs H. S. (1991) Cotreatment with growth hormone after pituitary suppression for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility, 56, 1104-1110.
34. Pekonen F., Laatikainen T., Buyalos R. and Rutanen E. (1989) Decreased 34K insulin-like growth factor binding protein in polycystic ovary disease. Fertility and Sterility, 51, 972-975.
35. Polson D. W., Adams J., Wadsworth J. and Franks S. (1988) Polycystic ovaries - a common finding in normal women. Lancet, 1, 870-872.
36. Poretsky L. and Piper B. (1994) Insulin resistance, hypersecretion of LH, and dual-defect hypothesis for the pathogenesis ovary syndrome. Obstetrics and Gynecology, 84, 613-621.
37. Prelevic G. M., Wurzburger M. I., Balint-Peric L. and Nesic J. S. (1990) Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet, 336, 900-903.
38. Prelevic G. M., Wurzburger M. I. and Balint-Peric L. (1992a) The effect of somatostatin analog octreotide (sandostatin) on luteinizing hormone and ovarian steroids in insulin-dependent diabetic women without residual insulin secretion. Gynecological Endocrinology, 6, 259-263.
39. Prelevic G. M., Wurzburger M. I., Balint-Peric L., Hardiman P., Okolo S., Maletic D. and Ginsburg J. (1992b) Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome. Metabolism, 41, supplement 2, 76-79.
40. Prelevic G. M., Ginsburg J., Maletic D., Hardiman P., Okolo S., Balint-Peric L., Thomas M. and Orskov H. (1995) The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Human Reproduction, 10, 28-32.
41. Reichlin S. (1983) Somatostatin. (Part I and III). New England Journal of Medicine, 309, 1495-1503, 1556-1563.
42. Reis R. M., Foss M. C., de Moura M. D., Ferriani R. A. and Silva de Sà M. F. (1995) Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism. Gynecological Endocrinology, 9, 45-50.
43. Rosenbaum D., Haber R. S. and Dunaif A. (1993) Insulin resistance in polycystic ovary syndrome decreased expression of GLUT-4 glucose transporters in adipocytes. American Journal of Physiology, 264, 197-202.
44. Ruutiainen K. and Adashi E. Y. (1993) Intraovarian factors in hyperandrogenism. Seminars in Reproductive Endocrinology, 11, 324-328.
45. Sharp P. S., Kiddy D. S., Reed M. J., Anyaoku V., Johnston D. G. and Franks S. (1991) Correlation of plasma insulin and insulin-like growth factor-1 with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clinical Endocrinology, 35, 253-257.
46. Shoham Z., Jacobs H. S. and Insler V. (1993) Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertility and Sterility, 59, 1153-1161.
47. Suikkari A. M., Ruutiainen K., Erkkola R. and Seppala M. (1989) Low levels of low molecular weight insulin-liked growth factor-binding protein in patients with polycystic ovarian disease. Human Reproduction, 4, 136-139.
48. Sutterlin M. and Steck T. (1995) Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism. Gynecological Endocrinology, 9, 37-44.
49. Taylor S. I., Dons R. F., Hernandez E., Roth J. and Gorden P. (1982) Insulin resistance associated with androgen axcess in women with autoantibodies to the insulin receptor. Annals of Internal Medicine, 97, 851-855.
50. Velazquez, E. M., Mendoza S., Hamer T., Sosa F. and Glueck C. J. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654.